106 related articles for article (PubMed ID: 29985199)
1. Colorectal Cancer Stratification in the Routine Clinical Pathway: A District General Hospital Experience.
Wedden S; Miller K; Frayling IM; Thomas T; Chefani A; Miller K; Hamblin A; Taylor JC; D'Arrigo C
Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):e54-e62. PubMed ID: 29985199
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
[TBL] [Abstract][Full Text] [Related]
3. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.
Boissière-Michot F; Frugier H; Ho-Pun-Cheung A; Lopez-Crapez E; Duffour J; Bibeau F
Virchows Arch; 2016 Aug; 469(2):135-44. PubMed ID: 27220764
[TBL] [Abstract][Full Text] [Related]
5. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers.
Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK
Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic and Molecular Characteristics of Synchronous Colorectal Carcinoma With Mismatch Repair Deficiency.
Nakano K; Yamamoto H; Fujiwara M; Koga Y; Tsuruta S; Ihara E; Oki E; Nakamura M; Ogawa Y; Oda Y
Am J Surg Pathol; 2018 Feb; 42(2):172-182. PubMed ID: 28877066
[TBL] [Abstract][Full Text] [Related]
8. Systematic immunohistochemical screening for Lynch syndrome in colorectal cancer: a single centre experience of 486 patients.
Zumstein V; Vinzens F; Zettl A; Heinimann K; Koeberle D; von Flüe M; Bolli M
Swiss Med Wkly; 2016; 146():w14315. PubMed ID: 27152634
[TBL] [Abstract][Full Text] [Related]
9. Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts.
Buchanan DD; Clendenning M; Rosty C; Eriksen SV; Walsh MD; Walters RJ; Thibodeau SN; Stewart J; Preston S; Win AK; Flander L; Ouakrim DA; Macrae FA; Boussioutas A; Winship IM; Giles GG; Hopper JL; Southey MC; English D; Jenkins MA
J Gastroenterol Hepatol; 2017 Feb; 32(2):427-438. PubMed ID: 27273229
[TBL] [Abstract][Full Text] [Related]
10. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A
Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358
[TBL] [Abstract][Full Text] [Related]
12. BRAF V600E mutation analysis simplifies the testing algorithm for Lynch syndrome.
Jin M; Hampel H; Zhou X; Schunemann L; Yearsley M; Frankel WL
Am J Clin Pathol; 2013 Aug; 140(2):177-83. PubMed ID: 23897252
[TBL] [Abstract][Full Text] [Related]
13. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
14. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
[TBL] [Abstract][Full Text] [Related]
15. [Screening for Lynch syndrome in colorectal cancer].
Liu X; Cao Y; Wang C; Cao R; Chen X; Ding J; Geng M
Zhonghua Bing Li Xue Za Zhi; 2014 Jun; 43(6):394-8. PubMed ID: 25208990
[TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
17. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening.
Bessa X; Ballesté B; Andreu M; Castells A; Bellosillo B; Balaguer F; Castellví-Bel S; Paya A; Jover R; Alenda C; Titó L; Martinez-Villacampa M; Vilella A; Xicola RM; Pons E; Llor X;
Clin Gastroenterol Hepatol; 2008 Feb; 6(2):206-14. PubMed ID: 18096441
[TBL] [Abstract][Full Text] [Related]
18. Detection of DNA Mismatch Repair Protein Abnormalities in Sudanese Colorectal Cancer Patients Using Immunohistochemical Methods.
Zakout YM; Lanza G
J Gastrointest Cancer; 2019 Sep; 50(3):530-536. PubMed ID: 29850986
[TBL] [Abstract][Full Text] [Related]
19. Identification of HNPCC by molecular analysis of colorectal and endometrial tumors.
Vasen HF; Hendriks Y; de Jong AE; van Puijenbroek M; Tops C; Bröcker-Vriends AH; Wijnen JT; Morreau H
Dis Markers; 2004; 20(4-5):207-13. PubMed ID: 15528786
[TBL] [Abstract][Full Text] [Related]
20. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency.
Clay MR; Allison KH; Folkins AK; Longacre TA
Am J Surg Pathol; 2014 Nov; 38(11):1494-500. PubMed ID: 24921635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]